Kenneth W Mahaffey Selected Research

Symporters

1/2022	Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
12/2021	Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial.
1/2021	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials.
11/2020	The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.
1/2020	Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.
1/2020	Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
6/2018	Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review.
1/2017	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
9/2015	Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.
8/2013	Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenneth W Mahaffey Research Topics

Disease

149	Hemorrhage 03/2022 - 12/2002
149	Myocardial Infarction 03/2022 - 07/2001
132	Stroke (Strokes) 01/2022 - 12/2002
110	Acute Coronary Syndrome 01/2022 - 07/2001
105	Atrial Fibrillation 10/2022 - 06/2006
57	Type 2 Diabetes Mellitus (MODY) 10/2022 - 05/2010
56	Heart Failure 10/2022 - 06/2002
50	Embolism (Embolus) 01/2022 - 06/2008
41	Thrombosis (Thrombus) 03/2022 - 06/2008
41	Ischemia 03/2022 - 01/2002
29	ST Elevation Myocardial Infarction 01/2022 - 09/2003
29	Peripheral Arterial Disease 01/2022 - 07/2012
28	Cardiovascular Diseases (Cardiovascular Disease) 10/2022 - 11/2005
25	Chronic Renal Insufficiency 10/2022 - 07/2008
17	Infarction (Infarctions) 09/2013 - 01/2002
14	Albuminuria 01/2022 - 08/2016
14	Body Weight (Weight, Body) 01/2021 - 03/2010
13	Ischemic Stroke 10/2022 - 09/2011
13	Kidney Diseases (Kidney Disease) 01/2022 - 07/2015
13	Diabetes Mellitus 01/2022 - 06/2002
12	Infections 01/2022 - 09/2003
12	Transient Ischemic Attack 01/2022 - 02/2010
11	Unstable Angina 01/2022 - 07/2001
11	Coronary Artery Disease (Coronary Atherosclerosis) 04/2021 - 07/2006
10	Intracranial Hemorrhages (Intracranial Hemorrhage) 10/2021 - 02/2004
10	Secondary Hyperparathyroidism 03/2016 - 09/2007
9	Diabetic Nephropathies (Diabetic Nephropathy) 09/2022 - 01/2019
9	Hypertension (High Blood Pressure) 01/2021 - 02/2010
8	Renal Insufficiency (Renal Failure) 01/2022 - 09/2010
6	Chronic Kidney Failure (Chronic Renal Failure) 12/2021 - 12/2017
6	Hemorrhagic Stroke 01/2019 - 10/2012
6	Coronary Disease (Coronary Heart Disease) 01/2019 - 06/2006
5	Inflammation (Inflammations) 12/2021 - 10/2005
5	Heart Diseases (Heart Disease) 12/2021 - 04/2006
5	Stable Angina 11/2018 - 05/2012
5	Sudden Death 01/2016 - 10/2012
5	Shock 10/2013 - 09/2003
4	Cardiac Arrhythmias (Arrythmia) 10/2022 - 03/2012
4	Chronic Obstructive Pulmonary Disease (COPD) 01/2021 - 03/2014

Drug/Important Bio-Agent (IBA)

65	Warfarin (Coumadin)FDA LinkGeneric 01/2022 - 02/2010
62	Clopidogrel (Plavix)FDA Link 01/2022 - 05/2008
59	CanagliflozinIBA 10/2022 - 08/2013
56	RivaroxabanIBA 01/2022 - 06/2008
41	Vitamin K FDA Link 01/2022 - 01/2013
38	TicagrelorIBA 01/2022 - 09/2009
34	Factor Xa (Coagulation Factor Xa)IBA 01/2022 - 02/2012
33	cangrelorIBA 03/2022 - 12/2009
30	AnticoagulantsIBA 01/2022 - 11/2003
28	CreatinineIBA 01/2022 - 06/2002
26	Enoxaparin (Lovenox)FDA LinkGeneric 12/2021 - 01/2003
23	vorapaxarIBA 07/2020 - 03/2009
22	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2005
21	Heparin (Liquaemin)FDA LinkGeneric 03/2019 - 12/2002
20	Thrombin Receptors (Thrombin Receptor)IBA 01/2022 - 01/2012
20	Glycoproteins (Glycoprotein)IBA 01/2020 - 04/2002
19	Glucose (Dextrose)FDA LinkGeneric 09/2022 - 07/2004
19	Pharmaceutical PreparationsIBA 01/2021 - 09/2003
17	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 09/2017 - 09/2004
15	SodiumIBA 09/2022 - 08/2013
14	Sodium-Glucose Transporter 2 InhibitorsIBA 10/2022 - 09/2015
14	omega-Chloroacetophenone (Mace)IBA 01/2022 - 12/2013
14	pexelizumabIBA 11/2013 - 09/2003
12	Sodium-Glucose Transport ProteinsIBA 10/2022 - 03/2015
11	AlbuminsIBA 01/2022 - 12/2017
11	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 06/2006
11	Cinacalcet (Sensipar)FDA Link 03/2016 - 09/2007
11	Complement System Proteins (Complement)IBA 09/2013 - 09/2003
10	SymportersIBA 01/2022 - 08/2013
10	MB Form Creatine KinaseIBA 10/2014 - 09/2003
9	Factor Xa InhibitorsIBA 01/2020 - 07/2010
9	Streptokinase FDA Link 06/2019 - 02/2004
9	Creatine Kinase (Creatine Phosphokinase)IBA 10/2014 - 08/2005
8	AntithrombinsIBA 09/2010 - 12/2003
6	N(4)-oleylcytosine arabinosideIBA 01/2021 - 12/2016
6	alirocumabIBA 12/2020 - 11/2014
6	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2018 - 08/2005
6	TroponinIBA 08/2017 - 05/2007
5	apixabanIBA 01/2022 - 07/2010
5	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 12/2021 - 12/2003
5	Peptide Hydrolases (Proteases)FDA Link 07/2020 - 03/2014
5	Anti-Arrhythmia AgentsIBA 01/2020 - 07/2013
5	pro-brain natriuretic peptide (1-76)IBA 12/2018 - 04/2006
5	Platelet Membrane Glycoprotein IIbIBA 05/2015 - 12/2002
5	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 03/2010 - 12/2002
4	DiureticsIBA 10/2022 - 01/2021
4	MineralsIBA 01/2022 - 07/2012
4	Insulin (Novolin)FDA Link 01/2022 - 03/2015
4	Hemoglobins (Hemoglobin)IBA 12/2021 - 03/2008
4	oxidized low density lipoproteinIBA 12/2020 - 11/2014

Therapy/Procedure

118	Therapeutics 09/2022 - 07/2001
54	Percutaneous Coronary Intervention 03/2022 - 09/2003
40	Stents 03/2022 - 12/2003
24	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2019 - 09/2004
15	Surgical Amputation (Amputations) 01/2022 - 09/2007
11	Renal Dialysis (Hemodialysis) 07/2020 - 09/2007
10	Patient Readmission 03/2017 - 11/2005
9	Secondary Prevention 01/2022 - 06/2008
8	Blood Transfusion (Blood Transfusions) 01/2018 - 07/2004
6	Thrombolytic Therapy 11/2017 - 12/2003
4	Drug Therapy (Chemotherapy) 06/2021 - 07/2010